Sittner & Nelson’s Regeneron Pharmaceuticals REGN Stock Holding History

Sittner & Nelson’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$73.4K	Hold	95	–	–	0.03%	262
2025 Q4	$74.6K	Hold	95	–	–	0.03%	239
2025 Q3	$53.4K	Hold	95	–	–	0.02%	250
2025 Q2	$49.9K	Hold	95	–	–	0.02%	251
2025 Q1	$60.3K	Hold	95	–	–	0.03%	219
2024 Q4	$67.7K	Hold	95	–	–	0.03%	199
2024 Q3	$99.9K	Hold	95	–	–	0.04%	178
2024 Q2	$99.8K	Hold	95	–	–	0.05%	161
2024 Q1	$91.4K	Hold	95	–	–	0.05%	164
2023 Q4	$83.4K	Hold	95	–	–	0.04%	167
2023 Q3	$78.2K	Hold	95	–	–	0.05%	164
2023 Q2	$68.3K	Hold	95	–	–	0.04%	183
2023 Q1	$78.1K	Buy	95 +20	+27%	+$15.1K	0.04%	179
2022 Q4	$54.1K	Hold	75	–	–	0.03%	210
2022 Q3	$52K	Sell	75 -28	-27%	-$17.6K	0.03%	202
2022 Q2	$61K	Buy	103 +28	+37%	+$18.2K	0.04%	197
2022 Q1	$52K	Hold	75	–	–	0.03%	207
2021 Q4	$47K	Hold	75	–	–	0.03%	212
2021 Q3	$45K	Hold	75	–	–	0.03%	198
2021 Q2	$42K	Hold	75	–	–	0.03%	190
2021 Q1	$35K	Hold	75	–	–	0.03%	197
2020 Q4	$36K	Buy	+75	New	+$40.5K	0.03%	186

Other funds holding REGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Sittner & Nelson's REGN Position: Q1 2026 in Review

Sittner & Nelson held its Regeneron Pharmaceuticals (REGN) position steady in Q1 2026 at 95 shares worth $73.4K. The position accounts for 0.03% of the portfolio, ranked #262.

Sittner & Nelson first reported a position in REGN in Q4 2020 and has held it in 22 quarters since. The position peaked at $99.9K in Q3 2024. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

Sittner & Nelson held 95 shares of Regeneron Pharmaceuticals worth $73.4K as of Q1 2026.
Sittner & Nelson left its Regeneron Pharmaceuticals share count unchanged in Q1 2026.
Regeneron Pharmaceuticals made up 0.03% of Sittner & Nelson's portfolio in Q1 2026, its #262 holding.
Sittner & Nelson first reported a position in Regeneron Pharmaceuticals in Q4 2020 and has held it in 22 quarters since.
Sittner & Nelson's Regeneron Pharmaceuticals position peaked at $99.9K in Q3 2024.
1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Sittner & Nelson's 13F filing for Q1 2026, filed 12 May 2026.